PNC Financial Services Group
CYCN icon

PNC Financial Services Group’s Cyclerion Therapeutics CYCN Stock Holding History

PNC Financial Services Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$5 – 4818
2024
Q2 		$5 Buy
+2
New +$6 ﹤0.01% 4753
2019
Q4 		– Hold
0
– – – 4007
2019
Q3 		– Sell
-1
Closed -$216 – 4008
2019
Q2 		$0 Buy
+1
New +$283 ﹤0.01% 4034

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PNC Financial Services Group's CYCN Position: Q3 2024 in Review

PNC Financial Services Group sold out of Cyclerion Therapeutics (CYCN) in Q3 2024, closing a stake of 2 shares — an estimated $5 sold.

PNC Financial Services Group first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $5 in Q2 2024. 15 funds tracked by Wall St. Rank hold CYCN as of Q3 2024.

  • PNC Financial Services Group reported no remaining Cyclerion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 2 Cyclerion Therapeutics shares in Q3 2024, an estimated $5.
  • PNC Financial Services Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
  • PNC Financial Services Group's Cyclerion Therapeutics position peaked at $5 in Q2 2024.
  • 15 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.